BBR Partners’s Third Harmonic Bio THRD Stock Holding History

BBR Partners’s Portfolio THRD Stock Details THRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30,000	Closed	-$104K	–	264
2025 Q1	$104K	Buy	+30,000	New	+$145K	0.01%	229

Other funds holding THRD

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

BBR Partners's THRD Position: Q2 2025 in Review

BBR Partners sold out of Third Harmonic Bio (THRD) in Q2 2025, closing a stake of 30,000 shares — an estimated $104K sold.

BBR Partners first reported a position in THRD in Q1 2025 and held it in 1 quarter. The position peaked at $104K in Q1 2025. 105 funds tracked by Wall St. Rank hold THRD as of Q2 2025.

BBR Partners reported no remaining Third Harmonic Bio position as of Q2 2025 after selling out during the quarter.
BBR Partners sold 30,000 Third Harmonic Bio shares in Q2 2025, an estimated $104K.
BBR Partners first reported a position in Third Harmonic Bio in Q1 2025 and held it in 1 quarter.
BBR Partners's Third Harmonic Bio position peaked at $104K in Q1 2025.
105 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q2 2025.

Based on BBR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.